Harnessing PPAR pharmacology through dual incretin-directed delivery.
Where this comes from
- Record sourced from PubMed, PMID 42102815.
- Also identified by DOI 10.1016/j.cmet.2026.04.009.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In Nature, Liskiewicz et al.<sup>1</sup> describe a unimolecular conjugate that combines GLP-1R/GIPR co-agonism with pan-PPAR nuclear hormone receptor activation, yielding a quintuple receptor agonist that links incretin signaling to PPAR-mediated transcriptional control within a single therapeutic scaffold.